Aging and Metabolism Stem Cells and Cancer
Adult stem cells ensure maintenance of the tissue and integrity in response to damage. They self-renew, are multipotential, and respond to and repair injuries. The skin and other stratified epithelia as model tissues display a high turnover rate, and contain well-defined populations of adult stem cells (SCs). A key feature of SCs is that they localize to specialized niches, where they remain unspecified but sense the needs of the tissue. Constant tissue replenishment drives a SCs to proliferate, the daughter cells to egress the niche, propagate, and terminally differentiate. Niche adherence, dormancy, activation, and exit, must be finely regulated processes, since loss of this tight control is causative of aging, and the onset and progression of squamous cell carcinomas.
Our global aim is to characterize the molecular pathways that regulate the behaviour of normal stem cells during homeostasis, and how they become deregulated during carcinogenesis and ageing.
Epidermal stem cells from mouse tail skin visualized by wholemount 3D immunostaining: Left panel shows epidermal stem cells marked with BrDU (Label Retaining Cells); Middle and right panels Show expression of keratin-15 and high expression of integrin alpha6, respectively.
We are interested in studying the following questions:
- What intrinsic (cell autonomous) mechanisms regulate adult stem cell function, and how are they deregulated during ageing and cancer?
- How do adult stem cells communicate with their local environment (i.e. niche) and how is the system coordinated to dictate stem cell function?
- What systemic cues communicate with adult stem cells and how do distant adult stem cells either from the same tissue or from different tissues coordinate their function at the level of the whole organism?
- How does deregulation of pathways that control stem cell behaviour contribute to the maintenance and invasive progression of skin and oral squamous cell carcinomas (SCC)? Is there cancer stem cell heterogeneity in human SCC? If so, what is its significance?
We use a combination of conditional mouse models, primary cell culture (human and mouse), live microscopy, highthroughput genomics and proteomics approaches, and basic molecular biology.
This group is financially supported by the following:
- Ministerio de Economía y Competitividad (MINECO)
- European Commission (EC), Fondo Europeo de Desarrollo Regional (FEDER), "Una manera de hacer Europa"
"Mecanismo de acción e inhibicion terapéutica de la población de celulas stem de la metástasis sensibles a la dieta" Ministerio de Economía y Competitividad and Fondo Europeo de Desarrollo Regional (FEDER-UE). Reference: BFU2016-79242-P
Grup de Recerca consolidat (SGR 2017-2019) Secretaria d'Universitats i Recerca del Departament d'Empresa i Coneixement de la Generalitat de Catalunya. Agencia de Gestió d'Ajuts Universitaris i de Recerca (AGAUR). Reference: 2017 SGR 1109
"Studying and targeting diet-responsive metastasis initiating cells" Worldwide Cancer Research (WCR). Referencia: 18-0133
"Células madre y cáncer" Fundación Botin (Banco Santander)
"Dietary Influences on Metastasis: How, When, and Why" (LIPOMET) European Research Council (ERC) under Horizon 2020 Programme. Reference: 787041
"Identificación de nuevas estrategias terapéuticas contra las células iniciadoras de la metástasis". Fundación Cientifica de la Asociación Española contra el Cáncer (FCAECC). Reference: PROYE19006AZNA
Group news & mentions
Salvador Aznar-Benitah wins the Liliane Bettencourt Prize for Life Sciences
Ona Therapeutics raises €30M in Series A financing
Gloria Pascual: research led by Joan Massagué “paves the way for the development of new drugs”
Salvador Aznar Benitah receives the “Premio Fundación Carmen y Severo Ochoa 2019”
09MarBiostatistics / Bioinformatics Unit: Get started on Statistical Concepts, Experimental Design and Exploratory Tools
10MarSpatial-proteomics reveal in-vivo phospho-signaling dynamics at subcellular resolution [IRB Research Nodes Seminar]
12MarImprovement of the efficacy and persistence of academic CAR-T cells for the treatment of mature-B cell malignancies